Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science [PDF]
Clinical and Translational ScienceIbrexafungerp is a first‐in‐class triterpenoid antifungal that targets β‐(1,3)‐glucan synthase in fungal cell wall development. It is indicated for vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC) in adult and post‐menarchal ...
Adelynne H. Walley +3 more
doaj +5 more sources
Repurposing therapy of ibrexafungerp vulvovaginal candidiasis drugs as cancer therapeutics [PDF]
Frontiers in Pharmacologyimpact ...
Tedi Rustandi +8 more
doaj +8 more sources
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections [PDF]
Journal of Fungi, 2022 Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to currently recommended antifungal therapies.
David A. Angulo +9 more
doaj +11 more sources
Candida glabrata Prosthetic Joint Infection Managed with Ibrexafungerp [PDF]
Journal of FungiWe report a case of a triazole and echinocandin-resistant C. glabrata right shoulder prosthetic joint infection in a 60-year-old woman. The patient underwent surgery and received the novel triterpenoid antifungal agent ibrexafungerp.
Ella Nadarevic +2 more
doaj +4 more sources
Real-World Ibrexafungerp Use Patterns Among Patients with Commercial Health Insurance, United States, 2021–2023 [PDF]
Drugs - Real World OutcomesBackground Vulvovaginal candidiasis (VVC) is a common gynecological complaint. Ibrexafungerp (brand name: Brexafemme®) is a new, first-in-class oral antifungal medication approved as a 1-day treatment for VVC and as a monthly treatment to reduce ...
Kaitlin Benedict +2 more
doaj +4 more sources
Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials [PDF]
HeliyonBackground: This study aims to evaluate the efficacy and safety associated with ibrexafungerp in the treatment of vulvovaginal candidiasis infection patients.
Rong He, Fei Lin, Bin Yu, Ling Huang
doaj +5 more sources
In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study [PDF]
Frontiers in Cellular and Infection Microbiology, 2022 BackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.ObjectiveThe aim of this study was to assess the in vitro activity of ibrexafungerp ...
Guillermo Quindós +32 more
doaj +8 more sources
Ibrexafungerp prolongs survival and reduces the eumycetoma grain size in Galleria mellonella infection models of two different causative agents of eumycetoma. [PDF]
J Antimicrob ChemotherOBJECTIVES: Eumycetoma is a neglected tropical fungal disease of the subcutaneous tissue that is currently not treatable with medication only. Standard itraconazole therapy is combined with surgical excision of the lesion.
Ma J +5 more
europepmc +5 more sources
Tn-seq screens in Candida glabrata treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance [PDF]
mSphereCandida glabrata (also known as Nakaseomyces glabratus) is the second most common cause of candidiasis, next to Candida albicans, and is rising in prevalence due to intrinsic and acquired mechanisms of antifungal resistance.
Timothy J. Nickels, Kyle W. Cunningham
doaj +3 more sources
Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B. [PDF]
Antimicrob Agents ChemotherIbrexafungerp (formerly SCY-078) is the first member of the triterpenoid class that prevents the synthesis of the fungal cell wall polymer β-(1,3)-D-glucan by inhibiting the enzyme glucan synthase.
Gebremariam T +8 more
europepmc +4 more sources